Lipoprotein lipase in hemodialysis patients: Indications that low molecular weight heparin depletes functional stores, despite low plasma levels of the enzyme

BMC Nephrology

Volumn 5, Issue , 2004, Pages

  Näsström, Birgit ^a   Stegmayr, Bernd ^a   Olivecrona, Gunilla ^a   Olivecrona, Thomas ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; HEPARIN; LIPOPROTEIN LIPASE; LOW MOLECULAR WEIGHT HEPARIN; TRIACYLGLYCEROL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIALYSIS; ENZYME BLOOD LEVEL; FEMALE; HEMODIALYSIS; HUMAN; MALE; MEASUREMENT;

AGED; AREA UNDER CURVE; DALTEPARIN; HEPARIN; HUMANS; KIDNEY DISEASES; LIPOPROTEIN LIPASE; REFERENCE VALUES; RENAL DIALYSIS; TRIGLYCERIDES;

EID: 12244298959     PISSN: 14712369     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-5-17     Document Type: Article

References (36)

1. Goldberg IJ, Merkel M: Lipoprotein lipase: physiology, biochemistry, and molecular biology. Front Biosci 2001, 6:D388-D405.
2. Olivecrona T, Olivecrona G: Lipoprotein and hepatic lipases in lipoprotein metabolism. In Lipoproteins in health and disease Edited by: Betteridge DJ, Illingworth DR and Shepherd J. London, Arnold; 1999:223-246.
3. Brunzell JD: Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. In Metabolic basis of inherited disease 7th edition. Edited by: Scriver CR, Beaudet AL, Sly WS and Valle D. New York, McGraw-Hill Book Co; 1995:1913-1932.
4. Preiss-Landl K, Zimmermann R, Hammerle G, Zechner R: Lipoprotein lipase: the regulation of tissue specific expression and its role in lipid and energy metabolism. Curr Opin Lipidol 2002, 13:471-481.
5. Bagdade JD: Uremic lipemia. An unrecognized abnormality in triglyceride production and removal. Arch Intern Med 1970, 126:875-881.
6. Chan MK, Persaud J, Varghese Z, Moorhead JF: Pathogenic roles of post-heparin lipases in lipid abnormalities in hemodialysis patients. Kidney Int 1984, 25:812-818.
7. Arnadottir M, Nilsson-Ehle P: Parathyroid hormone is not an inhibitor of lipoprotein lipase activity. Nephrol Dial Transplant 1994, 9:1586-1589.
8. Bagdade JD, Porte DJ, Bierman EL: Hypertriglyceridemia. A metabolic consequence of chronic renal failure. N Engl J Med 1968, 279:181-185.
9. Nestel PJ: The depletion and restoration of post-heparin lipolytic activity in the human forearm. Proc Soc Exp Biol Med 1970, 134:896-899.
10. Schrader J, Andersson LO, Armstrong VW, Kundt M, Stibbe W, Scheler F: Lipolytic effects of heparin and low molecular weight heparin and their importance in hemodialysis. Semin Thromb Hemost 1990, 16 Suppl:41-45.
11. Weintraub M, Rassin T, Eisenberg S, Ringel Y, Grosskopf I, Iaina A, Charach G, Liron M, Rubinstein A: Continuous intravenous heparin administration in humans causes a decrease in serum lipolytic activity and accumulation of chylomicrons in circulation. J Lipid Res 1994, 35:229-238.
12. Näsström B, Olivecrona G, Olivecrona T, Stegmayr BG: Lipoprotein lipase during heparin infusion: lower activity in hemodialysis patients. Scand J Clin Lab Invest 2003, 63:45-53.
13. Harenberg J, Roebruck P, Heene DL: Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. The Heparin Study in Internal Medicine Group. Haemostasis 1996, 26:127-139.
14. Sagedal S, Hartmann A, Sundstrom K, Bjornsen S, Fauchald P, Brosstad F: A single dose of dalteparin effectively prevents clotting during haemodialysis. Nephrol Dial Transplant 1999, 14:1943-1947.
15. Persson E: Lipoprotein lipase, hepatic lipase and plasma lipolytic activity. Effects of heparin and a low molecular weight heparin fragment (Fragmin). Acta Med Scand Suppl 1988, 724:1-56.
16. Kronenberg F, König P, Lhotta K, Steinmetz A, Dieplinger H: Low molecular weight heparin does not necessarily reduce lipids and lipoproteins in hemodialysis patients. Clin Nephrol 1995, 43:399-404.
17. Lookene A, Chevreuil O, Ostergaard P, Olivecrona G: Interaction of lipoprotein lipase with heparin fragments and with heparan sulfate: stoichiometry, stabilization and kinetics. Biochemistry 1996, 35:12155-12163.
18. van Tilbeurgh H, Roussel A, Lalouel JM, Cambillau C: Lipoprotein lipase. Molecular model based on the pancreatic lipase X-ray structure: consequences for heparin binding and catalysis. J Biol Chem 1994, 269:4626-4633.
19. Holmer E: Low-molecular weight heparin. In Heparin Edited by: Lane D and Lindahl U. Edward Arnold Publishers Ltd, London: England; 1989:575-595.
20. Chevreuil O, Hultin M, Ostergaard P, Olivecrona T: Heparin- decasaccharides impair the catabolism of chylomicrons. Biochem J 1996, 320:437-444.
21. Liu G, Bengtsson-Olivecrona G, Østergaard PB, Olivecrona T: Low-Mr heparin is as potent as conventional heparin in releasing lipoprotein lipase, but is less effective in preventing hepatic clearance of the enzyme. Biochem J 1991, 273:747-752.
22. Näsström B, Stegmayr BG, Olivecrona G, Olivecrona T: Lower plasma levels of lipoprotein lipase after infusion of low molecular weight heparin than after administration of conventional heparin indicate more rapid catabolism of the enzyme. J Lab Clin Med 2003, 142:90-99.
23. Näsström B, Olivecrona G, Olivecrona T, Stegmayr BG: Lipoprotein lipase during continuous heparin infusion: Tissue stores become partially depleted. J Lab Clin Med 2001, 138:206-213.
24. Tornvall P, Olivecrona G, Karpe F, Hamsten A, Olivecrona T: Lipoprotein lipase mass and activity in plasma and their increase after heparin are separate parameters with different relations to plasma lipoproteins. Arterioscler Thromb Vasc Biol 1995, 15:1086-1093.
25. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
26. Olivecrona G, Hultin M, Savonen R, Skottova N, Lookene A, Tugrul Y, Olivecrona T: Transport of lipoprotein lipase in plasma and lipoprotein metabolism. In Atherosclerosis X Edited by: Woodford FP, Davignon J and Sniderman AD. Elsevier; 1995:250-253.
27. Persson E, Nordenström J, Nilsson-Ehle P, Hagenfeldt L: Lipolytic and anticoagulant activities of a low molecular weight fragment of heparin. Eur J Clin Invest 1985, 15:215-220.
28. Persson E, Nordenström J, Nilsson-Ehle P: Plasma kinetics of lipoprotein lipase and hepatic lipase activities induced by heparin and a low molecular weight heparin fragment. Scand J Clin Lab Invest 1987, 47:151-155.
29. Persson E, Nordenström J, Nilsson-Ehle P, Hagenfeldt L, Wahren J: Plasma lipolytic activity and substrate oxidation after intravenous administration of heparin and a low molecular weight heparin fragment. Clin Physiol 1990, 10:573-583.
30. Arnadottir M, Kurkus J, Nilsson-Ehle P: Different types of heparin in haemodialysis: Long-term effects on post-heparin lipases. Scand J Clin Lab Invest 1994, 54:515-521.
31. Chevreuil O, Hultin M, Østergaard PB, Olivecrona T: Depletion of lipoprotein lipase after heparin administration. Arterioscler Thromb 1993, 13:1391-1396.
32. Chevreuil O, Hultin M, Østergaard PB, Olivecrona T: Biphasic effects of low-molecular-weight and conventional heparins on chylomicron clearance in rats. Arterioscler Thromb 1993, 13:1397-1403.
33. Vaziri ND, Liang KH: Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int 1996, 50:1928-1935.
34. Ruge T, Neuger L, Sukonina V, Wu G, Barath S, Gupta J, Frankel B, Christophersen B, Nordstoga K, Olivecrona T, Olivecrona G: Lipoprotein lipase in kidney; activity varies widely between animal species. Am J Physiol Renal Physiol 2004.
35. Savonen R, Nordstoga K, Christophersen B, Lindberg A, Shen Y, Hultin M, Olivecrona T, Olivecrona G: Chylomicron metabolism in an animal model for hyperlipoproteinemia type I. J Lipid Res 1999, 40:1336-1346.
36. Cheung AK, Parker CJ, Ren K, Iverius PH: Increased lipase inhibition in uremia: identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma. Kidney Int 1996, 49:1360-1371.